With the completion of the localisation, the program is expected to include both the English and Greek versions of GeneMedRx rely to analyse complex medication regimens and DNA test results to identify interactions that can lead to treatment failure and adverse side effects.
Genelex sells DNA Drug Sensitivity testing and the GeneMedRx software to doctors to help them choose the safest medicines for their patients.
Howard Coleman, CEO of Genelex, said: “We’re delighted to be working with Papacharisis. He and his team are ideally placed to expand the usefulness of this product and to bring it to Greece and the wider European market. Following the launch of the software in Greece it is anticipated that other language versions will be jointly developed and sold throughout Europe.”
George Papacharisis, founder of Medigene, said: “GeneMedRx has the potential to improve patient care because it detects many more problematic drug interactions than competing products. We’re extremely pleased to be bringing the benefits of this comprehensive personalised medication management tool to our country.”